Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal

Fineline Cube Dec 16, 2025
Company Deals

uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials

Fineline Cube Dec 16, 2025
Company Deals

Dren Bio, Sanofi Forge $1.8B B‑Cell Therapy Deal with US Co‑Promote Option

Fineline Cube Dec 16, 2025
Company Deals

Adaptive Licenses TCR Data to Pfizer in $890M Deal for Rheumatoid Arthritis

Fineline Cube Dec 16, 2025
Company Deals

Sobi Acquires Arthrosi for $1.5 Billion to Add Gout Drug to Portfolio

Fineline Cube Dec 15, 2025
Policy / Regulatory

FDA Removes Key RWE Limitation, Allowing Drug and Device Submissions Without Individual Patient Data

Fineline Cube Dec 16, 2025
Company Drug

Orelabrutinib First BTK Inhibitor to Hit Phase 3 in Lupus as InnoCare NMPA Filing Cleared

Fineline Cube Dec 16, 2025
Company Drug

ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy

Fineline Cube Dec 16, 2025
Company Deals

Shenzhen Core Medical Raises ‘Hundreds of Millions’ in Series C Financing

Fineline Cube Dec 30, 2022

Shenzhen-based heart failure mechanical circulatory support solutions provider, Shenzhen Core Medical Technology Co., Ltd, has...

Company

Sinovac Reports H1 2022 Financials Amid COVID-19 Vaccine Demand Decline

Fineline Cube Dec 30, 2022

China-based Sinovac Biotech Ltd (NASDAQ: SVA) has released its financial report for the first half...

Company Drug

Junshi Biosciences’ JT001 (VV116) Shows Non-Inferiority to Paxlovid in COVID-19 Trial

Fineline Cube Dec 29, 2022

The results of a Phase III clinical study for China-based Junshi Biosciences’ (HKG: 1877, SHA:...

Company Drug Legal / IP

Hainan Shuangcheng Files Paragraph IV Patent Declaration for Paclitaxel, Albumin-Bound

Fineline Cube Dec 29, 2022

China’s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHE: 002693) has announced a Paragraph IV patent declaration...

Company Drug

Grand Pharma’s COVID-19 Therapy GS221 Shows Promising Safety Profile

Fineline Cube Dec 29, 2022

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its clinical study for the...

Company Drug

Fosun Pharma Launches Online Registration for BioNTech COVID-19 Vaccine in Hong Kong

Fineline Cube Dec 29, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced a new initiative...

Company Drug

Immunotech Biopharm’s CAR-T-19-D2 IND Filing Accepted by NMPA

Fineline Cube Dec 29, 2022

China-based chimeric antigen receptor T-cell (CAR-T) specialist Immunotech Biopharm Ltd (HKG: 6978) has announced that...

Company Medical Device

Acotec Scientific Holdings Receives NMPA Approvals for YAN and P-Conic Balloon

Fineline Cube Dec 29, 2022

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving market approvals from the National...

Company Drug

CanSino Biologics Updates Data from COVID-19 Vaccine Clinical Studies

Fineline Cube Dec 29, 2022

China-based CanSino Biologics (HKG: 6185) has provided data updates from three clinical studies for its...

Company Deals

Fortune Care Raises Over RMB 100 Million in Series C+ Financing Round

Fineline Cube Dec 29, 2022

China-based household healthcare and nursing brand Fortune Care reportedly raised over RMB 100 million (USD...

Company Deals

Guangzhou Mygene Raises ‘Hundreds of Millions’ in Series C Financing Led by Efund Capital

Fineline Cube Dec 29, 2022

China-based molecular diagnostic product developer Guangzhou Mygene Medical Technology Co., Ltd reportedly raised “hundreds of...

Company

WuXi Biologics Receives First GMP Certificate from Ireland HPRA

Fineline Cube Dec 28, 2022

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced receiving...

R&D

CARsgen Develops New CAR-T Technique to Enhance Anti-Tumor Activity

Fineline Cube Dec 28, 2022

China-based chimeric antigen receptor (CAR)-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced...

Company Drug

SciClone Pharmaceuticals’ Vaborem IND Filing Accepted by NMPA

Fineline Cube Dec 28, 2022

SciClone Pharmaceuticals Inc (HKG: 6600) has announced that an Investigational New Drug (IND) filing for...

Company Drug

Luye Pharma’s Paliperidone Palmitate Accepted for NMPA Review

Fineline Cube Dec 28, 2022

China-based Luye Pharma Group (HKG: 2186) has announced that the market filing for its paliperidone...

Policy / Regulatory

China Downgrades COVID-19 from Class A to Class B Infectious Disease

Fineline Cube Dec 28, 2022

The National Health Commission (NHC) has issued a notice downgrading COVID-19 from a Class A...

Company Deals

Carrier Biomed Raises ‘Tens of Millions’ in Series A+ Financing Round

Fineline Cube Dec 28, 2022

Carrier Biomed (Soohow) Co., Ltd, an exosome technology developer based in Suzhou, has reportedly raised...

Company

Everest Medicines Launches First Phase of Global mRNA Vaccine Manufacturing Site

Fineline Cube Dec 28, 2022

China-based Everest Medicines (HKG: 1952) has announced the initiation of the operation of the first...

Company Drug

InnoCare Pharma Receives Hong Kong Approval for Tafasitamab in DLBCL

Fineline Cube Dec 28, 2022

China-based biopharma InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving market approval from the...

Company Deals

LeadArt Biotechnologies Raises USD 6 Million in Pre-Series A Round

Fineline Cube Dec 28, 2022

LeadArt Biotechnologies Inc., a chemical proteomics specialist based in Ningbo, has reportedly raised close to...

Posts pagination

1 … 513 514 515 … 598

Recent updates

  • Orelabrutinib First BTK Inhibitor to Hit Phase 3 in Lupus as InnoCare NMPA Filing Cleared
  • Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal
  • Zhicheng’s TAVR Robotic System Enters NMPA Innovation Pathway
  • ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy
  • FDA Removes Key RWE Limitation, Allowing Drug and Device Submissions Without Individual Patient Data
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Orelabrutinib First BTK Inhibitor to Hit Phase 3 in Lupus as InnoCare NMPA Filing Cleared

Company Deals

Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal

Company Medical Device

Zhicheng’s TAVR Robotic System Enters NMPA Innovation Pathway

Company Drug

ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.